Not sure, but I've read the japanese royalties are low single digit. Probably ok given DS funded all the trials themselves and BTA will leverage the ROW royalties.
Have to say that Biota has clever scientists... they need to look at the American example of successful biotechs. Keeping your stock price low just doesn't work in the long run.
